This point is critical for patients with CLL harboring p53 mutations, as it suggests that ibrutinib (and potentially other BTK-inhibitors) will be extremely effective in treating CLL when the p53 pathway is not fully functional. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.